Stephen O'Hara, chief executive of OptiBiotix talks to TPL

4 May 2016

Stephen O’Hara is chief executive of OptiBiotix Health (LSE: OPTI), a UK-based biotech which has been interesting big pharma recently with its Lactobacillus plantarum strain, a statin-free cholesterol pill. He spoke to the Pharma Letter about developing compounds to stop and manage not just high cholesterol levels but other human metabolic diseases such as obesity, lipid distribution and diabetes.

The following is a question and answer dialog:

Tell us a little bit about OptiBiotix?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK